We believe that science and data should be discussed, not just read.
Our videos are meant to provide additional information and context to enable everyone to meaningfully interpret the ongoing stream of information.
VBI-1901: SNO Phase 2a Data & Clinical Update
Jeff Baxter and David E. Anderson, Ph.D., discuss updated Phase 2a (Part B) data of VBI-1901 in recurrent GBM patients, as presented at SNO 2020.
Sci-B-Vac® Late-Breaker Oral Presentation at EASL 2020
Adam Finn, M.D., Ph.D., discusses Data from the Sci-B-Vac® Phase 3 program at EASL.
Preclinical Coronavirus Program Data Webcast
VBI discusses preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines.
VBI-1901: AACR Data and Clinical Update
VBI-1901: AACR 2020 Webcast
David E. Anderson, Ph.D., discusses updated Part B data from the VBI’s ongoing Phase 1/2a study of VBI-1901.
First- and Second-Generation Hepatitis B Vaccines
VBI-1901 Therapeutic Cancer Vaccine Design
Preclinical Studies in Glioblastoma (“GBM”)
In preclinical studies, VBI demonstrated that its vaccine candidate stimulated immune responses critical to efficacious anti-tumor immunity.
Next Steps in the Development of Sci-B-Vac™
Sci-B-Vac™ is a licensed third-generation hepatitis B vaccine that has demonstrated safety and efficacy in over 300,000 patients. Sci-B-Vac™ is currently approved for use in Israel and in 14 other countries.
About Medulloblastoma (“MB”)
Medulloblastoma is the most common malignant primary brain tumor in children.
About Glioblastoma (“GBM”)
Glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal, with median patient survival of less than sixteen months.
LPV™ Thermostability Platform
About Hepatitis B
Hepatitis B is a disease of the liver caused by the hepatitis B virus (“HBV”) characterized by inflammation, injury, and even cell death.
Cytomegalovirus (“CMV”) Vaccine Candidate
Enveloped Virus-Like Particle (“eVLP”) Platform Technology
